Live Analyst Rating Changes 24623 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Brandon Folkes
HC

Brandon Folkes

H.C. Wainwright
Wall Street Analyst
★★☆☆☆
#2747
on 13Foresight · ranked by our own returns
46%
Success Rate
-0.9%
Average Return
39 of 84 calls profitable · -3.8% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 46% of Brandon Folkes's ratings turned a profit when each position was held for 1 year — averaging -0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

221 Buy 2 Hold 0 Sell
Brandon's Stock Coverage 46 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VALN
Valneva
 Aug 14, 2026 BUY Strong Buy
+101.4% avg upside
6 analysts
$18.00
218.65% Upside
 +0.0% ·
CNTB
Connect Biopharma Holdings
 Aug 14, 2026 BUY Strong Buy
+157.7% avg upside
12 analysts
$7.00
175.54% Upside
 · ·
TSE:CRDL
Cardiol Therapeutics
 Aug 14, 2026 BUY Strong Buy
+368.5% avg upside
6 analysts
$12.54
418.03% Upside
 · ·
CRMD
Cormedix
 Aug 14, 2026 BUY Strong Buy
+83.9% avg upside
13 analysts
$13.00
59.70% Upside
 · ·
PTHS
Pelthos Therapeutics
 Aug 14, 2026 BUY Strong Buy
+96.1% avg upside
8 analysts
$60.00
107.19% Upside
 · ·
SINT
Sintx Technologies
 Aug 13, 2026 BUY Strong Buy
+372.0% avg upside
8 analysts
$10.00
484.85% Upside
 +0.0% ·
TLPH
Talphera
 Aug 13, 2026 BUY Buy
+289.8% avg upside
15 analysts
$3.00
147.99% Upside
 +2.5% ·
OMER
Omeros
 Aug 13, 2026 BUY Buy
+20.2% avg upside
14 analysts
$33.00
90.30% Upside
 -1.3% ·
DERM
Journey Medical Corp
 Aug 13, 2026 BUY Strong Buy
+79.9% avg upside
11 analysts
$13.00
95.42% Upside
 +0.0% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Aug 13, 2026 BUY Strong Buy
+140.4% avg upside
9 analysts
$15.32
64.48% Upside
 · ·
PYPD
PolyPid
 Aug 13, 2026 BUY Strong Buy
+231.3% avg upside
7 analysts
$13.00
172.06% Upside
 -1.7% ·
MIST
Milestone Pharmaceuticals
 Aug 13, 2026 BUY Strong Buy
+663.6% avg upside
7 analysts
$8.00
647.70% Upside
 +0.9% ·
ENTA
Enanta Pharmaceuticals
 Aug 11, 2026 BUY Buy
+142.8% avg upside
17 analysts
$20.00
48.73% Upside
 -1.0% ·
SGMT
Sagimet Biosciences, Inc. Class A
 Aug 11, 2026 BUY Strong Buy
+203.9% avg upside
15 analysts
$29.00
212.55% Upside
 +10.8% ·
TRVI
Trevi Therapeutics
 Aug 11, 2026 BUY Strong Buy
+32.8% avg upside
18 analysts
$24.00
32.19% Upside
 +4.1% ·
HRTX
Heron Therapeutics
 Aug 11, 2026 HOLD Strong Buy
+8543.4% avg upside
21 analysts
 — +3.1% ·
ANIP
ANI Pharmaceuticals
 Aug 11, 2026 BUY Strong Buy
+36.6% avg upside
11 analysts
$121.00
61.78% Upside
 +2.2% ·
ACHV
Achieve Life Sciences
 Aug 11, 2026 BUY Strong Buy
+115.2% avg upside
15 analysts
$12.00
65.51% Upside
 +0.0% ·
XERS
Xeris Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+15.2% avg upside
10 analysts
$10.00
20.09% Upside
 +8.5% ·
COLL
Collegium Pharmaceutical
 Aug 07, 2026 BUY Strong Buy
+44.1% avg upside
8 analysts
$60.00
113.07% Upside
 -4.3% ·
ZVRA
Zevra Therapeutics
 Aug 06, 2026 BUY Strong Buy
+95.5% avg upside
15 analysts
$26.00
132.50% Upside
 -4.7% ·
MNKD
MannKind
 Aug 06, 2026 BUY Buy
+88.9% avg upside
22 analysts
$10.00
168.05% Upside
 -2.3% ·
RNTX
Rein Therapeutics
 Aug 05, 2026 BUY Strong Buy
+1038.9% avg upside
6 analysts
$8.00
915.93% Upside
 +12.7% ·
INDV
Indivior
 Aug 04, 2026 BUY Strong Buy
-2.1% avg upside
10 analysts
$48.00
25.63% Upside
 +6.9% ·
RANI
Rani Therapeutics Holdings
 Jul 16, 2026 BUY Strong Buy
+1090.9% avg upside
10 analysts
$11.00
1278.53% Upside
 +19.4% ·
TRAW
Traws Pharma
 Jun 18, 2026 HOLD Buy
+5463.7% avg upside
10 analysts
$1.00
66.76% Upside
 -30.6% ·
ADIL
Adial Pharmaceuticals
 Mar 04, 2025 BUY Strong Buy
+932.9% avg upside
7 analysts
$200.00
4455.91% Upside
 -89.4% ·
RMTI
Rockwell Med
 Nov 14, 2024 BUY Buy
+110.1% avg upside
11 analysts
$5.00
36.02% Downside
 · ·
EBS
Emergent Biosolutions
 Aug 22, 2024 BUY Buy
+451.8% avg upside
9 analysts
$16.00
256.30% Upside
 -2.8% ·
CERS
Cerus
 May 03, 2024 BUY Strong Buy
+89.8% avg upside
10 analysts
$4.00
40.83% Upside
 -16.7% ·
ELUT
Elutia
 May 12, 2023 BUY Strong Buy
+845.0% avg upside
5 analysts
$10.00
1062.35% Upside
 +41.8% ·
OBSEF
ObsEva
 Mar 17, 2023 HOLD Buy
+1079999900.0% avg upside
8 analysts
 — · ·
IMVIF
IMV
 Mar 17, 2023 HOLD Buy
+153524409.4% avg upside
7 analysts
 — · ·
EGRX
Eagle Pharmaceuticals
 Mar 13, 2023 HOLD Strong Sell
+4101.7% avg upside
2 analysts
$33.00
5446.26% Upside
 · ·
VERU
Veru
 Feb 09, 2023 BUY Strong Buy
+627.3% avg upside
10 analysts
$15.00
455.51% Upside
 -90.4% ·
R
Ryder System
 Feb 03, 2023 BUY Strong Buy
-10.8% avg upside
15 analysts
$48.00
81.76% Downside
 +23.6% ·
RDHL
RedHill Biopharma
 Nov 22, 2022 BUY Strong Buy
+3265.3% avg upside
7 analysts
$40.00
6622.60% Upside
 · ·
SRNE
Sorrento Therapeutics
 Nov 02, 2022 BUY Strong Buy
+4508828.5% avg upside
7 analysts
$5.00
714185.77% Upside
 · ·
TRVN
Trevena
 Mar 31, 2022 BUY Buy
+1424900.0% avg upside
11 analysts
$50.00
4999899.95% Upside
 · ·
ALKS
Alkermes
 Jan 27, 2022 BUY Strong Buy
-16.3% avg upside
34 analysts
$32.00
35.24% Downside
 +18.2% ·
AXGN
AxoGen
 Nov 04, 2021 BUY Strong Buy
-27.1% avg upside
21 analysts
$25.00
48.04% Downside
 -16.6% ·
JAZZ
Jazz Pharmaceuticals
 Oct 06, 2021 BUY Strong Buy
-4.1% avg upside
35 analysts
$210.00
14.56% Downside
 +1.6% ·
VRAYQ
Viewray
 Aug 09, 2021 BUY Strong Buy
+558333233.3% avg upside
12 analysts
$8.00
799999900.00% Upside
 · ·
SMTI
Sanara MedTech
 Jun 30, 2021 BUY Buy
+14.7% avg upside
5 analysts
$45.00
31.80% Upside
 -43.5% ·
SIBN
SI-Bone
 Dec 15, 2020 BUY Strong Buy
+36.9% avg upside
18 analysts
$33.00
74.04% Upside
 -27.2% ·
PAHC
Phibro Animal Health
 Sep 12, 2016 BUY Hold
+9.2% avg upside
10 analysts
$30.00
11.98% Downside
 +39.8% ·
🔒 41 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Brandon Folkes — Frequently Asked Questions
How accurate are Brandon Folkes's stock ratings?
Based on the calls 13Foresight could measure, about 42% of Brandon's ratings were profitable over a one-year hold, with an average return of -1.7% per rating, or -4.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Brandon ranked on 13Foresight?
Brandon Folkes is currently ranked #2747 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Brandon cover?
Brandon most recently has ratings on VALN, CNTB, TSE:CRDL, CRMD, PTHS, SINT, TLPH, OMER, DERM, TSE:EPRX, PYPD, MIST and 34 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.